#PH94B - Twitter Search / Twitter
VistaGen to Present PH94B Exploratory Phase 2A Research Program for Adjustment Disorder with Anxiety at American Society for Clinical Psychopharmacology Annual Meeting
VistaGen: Phase 2 Success In Anxiety Disorder, Phase 3 To Begin (NASDAQ:VTGN) | Seeking Alpha
Psych News Alert: Experimental Nasal Spray May Treat Social Anxiety Disorder, Study Indicates
,%20Phobia,%20Social,%20Anxiety%20Disorders:%0A%0APH94B%20Nasal%20Spray%20for%20Social%20Anxiety%20Disorder%20(SAD).png?md=1 "PH94B Nasal Spray for Social Anxiety Disorder (SAD) Clinical Trial 2022 | Power")
PH94B Nasal Spray for Social Anxiety Disorder (SAD) Clinical Trial 2022 | Power
PDF) Effect of as-needed use of intranasal PH94B on social and performance anxiety in individuals with social anxiety disorder: L iebowitz et al.
Nasal spray to treat social anxiety disorder lacks abuse potential: FDA
VistaGen Reports Positive Preclinical Data Differentiating Mechanism of Action of PH94B from Risk-Ridden Benzodiazepines
VistaGen's Nasal Spray for Social Anxiety Disorder Falls Short in Phase III Trial | BioSpace
PH94B Nasal Spray for Anxiety Disorders | Vistagen Therapeutics, Inc
VistaGen: Phase 2 Success In Anxiety Disorder, Phase 3 To Begin (NASDAQ:VTGN) | Seeking Alpha
VistaGen readies Phase 3 trial of novel, fast-acting neuroactive nasal spray in social anxiety disorder - BioTuesdays
VistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B | Business Wire
PH94B Neuroactive Nasal Spray, a Potential On-Demand Treatment for Social Anxiety Disorder | Learn how PH94B, a novel, rapid-acting CNS neuroactive nasal spray being developed by VistaGen Therapeutics for the treatment of
VistaGen says FDA found no signal of abuse potential for its nasal spray PH94B for anxiety | Seeking Alpha
VistaGen's nasal spray wins US FDA fast-track designation for anxiety disorder | S&P Global Market Intelligence
PH94B Nasal Spray for Anxiety Disorders | Vistagen Therapeutics, Inc
Fasedienol - Wikipedia
vtgn10k_mar312020
VistaGen Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
Latest Pharma News Updates | VistaGen, Merck, CAMP4, Wugen, Incyte
